药物基因组学检测药物-基因相互作用对重度抑郁症药物选择及症状缓解的影响:PRIME Care随机临床试验
这项实用随机临床试验纳入22个退伍军人事务医疗中心的1944例重度抑郁症患者,比较药物基因组学检测指导治疗与常规护理。检测组开具预测存在药物-基因相互作用处方的比例更低,24周内缓解率略高,但第24周时缓解率无显著差异。
要点
- 药物基因组学检测指导组开具无药物-基因相互作用处方的估计风险为59.3%,常规护理组为25.7%。
- 检测组24周内缓解率高于常规护理组(OR 1.28,95%CI 1.05-1.57),风险差2.8%。
- 第24周时两组缓解率无显著差异(估计风险差1.5%,95%CI -2.4%至5.3%)。
核心结论
- 在重度抑郁症患者中,提供药物-基因相互作用药物基因组学检测减少了开具预测存在药物-基因相互作用处方的比例。
- 提供检测结果对症状缓解有微小且不持久的影响。
研究设计与样本
- 实用随机临床试验,比较药物基因组学检测指导治疗与常规护理。
- 纳入676名临床医生和1944例患者,来自22个退伍军人事务医疗中心,2017年7月至2021年2月入组,随访至2021年11月。
- 纳入标准为正在起始或换用单种抗抑郁药治疗的重度抑郁症患者;排除标准包括活跃物质使用障碍、躁狂、精神病或同时使用特定药物清单。
主要发现
- 药物基因组学指导组(n=966)接受无、中等、显著药物-基因相互作用抗抑郁药的估计风险分别为59.3%、30.0%、10.7%,常规护理组(n=978)分别为25.7%、54.6%、19.7%。
- 药物基因组学指导组更可能接受潜在药物-基因相互作用较低的药物:无 vs 中等/显著相互作用 OR 4.32(95%CI 3.47-5.39;P<.001);无/中等 vs 显著相互作用 OR 2.08(95%CI 1.52-2.84;P=.005);总体比较P<.001。
- 24周内缓解率在药物基因组学检测指导组高于常规护理组(OR 1.28,95%CI 1.05-1.57;P=.02;风险差2.8%,95%CI 0.6%-5.1%)。
- 第24周时,药物基因组学指导组130例和常规护理组126例达到缓解,估计风险差1.5%(95%CI -2.4%至5.3%;P=.45),差异无统计学显著。
关键数值与推荐
- 缓解定义为患者健康问卷-9(PHQ-9)≤5分。
- 共同主要结局为随机化后30天内开具的处方中具有预测药物-基因相互作用的比例,以及24周内盲法评估的抑郁症状缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 提供检测结果对症状缓解有微小且不持久的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Selecting effective antidepressants for the treatment of major depressive disorder (MDD) is an imprecise practice, with remission rates of about 30% at the initial treatment. OBJECTIVE: To determine whether pharmacogenomic testing affects antidepressant medication selection and whether such testing leads to better clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: A pragmatic, randomized clinical trial that compared treatment guided by pharmacogenomic testing vs usual care. Participants included 676 clinicians and 1944 patients. Participants were enrolled from 22 Department of Veterans Affairs medical centers from July 2017 through February 2021, with follow-up ending November 2021. Eligible patients were those with MDD who were initiating or switching treatment with a single antidepressant. Exclusion criteria included an active substance use disorder, mania, psychosis, or concurrent treatment with a specified list of medications. INTERVENTIONS: Results from a commercial pharmacogenomic test were given to clinicians in the pharmacogenomic-guided group (n = 966). The comparison group received usual care and access to pharmacogenomic results after 24 weeks (n = 978). MAIN OUTCOMES AND MEASURES: The co-primary outcomes were the proportion of prescriptions with a predicted drug-gene interaction written in the 30 days after randomization and remission of depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9) (remission was defined as PHQ-9 ≤ 5). Remission was analyzed as a repeated measure across 24 weeks by blinded raters. RESULTS: Among 1944 patients who were randomized (mean age, 48 years; 491 women [25%]), 1541 (79%) completed the 24-week assessment. The estimated risks for receiving an antidepressant with none, moderate, and substantial drug-gene interactions for the pharmacogenomic-guided group were 59.3%, 30.0%, and 10.7% compared with 25.7%, 54.6%, and 19.7% in the usual care group. The pharmacogenomic-guided group was more likely to receive a medication with a lower potential drug-gene interaction for no drug-gene vs moderate/substantial interaction (odds ratio [OR], 4.32 [95% CI, 3.47 to 5.39]; P < .001) and no/moderate vs substantial interaction (OR, 2.08 [95% CI, 1.52 to 2.84]; P = .005) (P < .001 for overall comparison). Remission rates over 24 weeks were higher among patients whose care was guided by pharmacogenomic testing than those in usual care (OR, 1.28 [95% CI, 1.05 to 1.57]; P = .02; risk difference, 2.8% [95% CI, 0.6% to 5.1%]) but were not significantly higher at week 24 when 130 patients in the pharmacogenomic-guided group and 126 patients in the usual care group were in remission (estimated risk difference, 1.5% [95% CI, -2.4% to 5.3%]; P = .45). CONCLUSIONS AND RELEVANCE: Among patients with MDD, provision of pharmacogenomic testing for drug-gene interactions reduced prescription of medications with predicted drug-gene interactions compared with usual care. Provision of test results had small nonpersistent effects on symptom remission. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03170362.
引用
- Oslin DW, Lynch KG, Shih MC, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022. PMID: 35819423. doi:10.1001/jama.2022.9805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。